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The skin has the potential for a variety of gene therapy appli-
cations. In addition to local delivery, it is the largest organ of 
the body, and highly vascular, and thus is an ideal site for 
systemic delivery of gene products. To evaluate the potential 
for adenovirus-mediated skin gene transfer, the replication-
deficient recombinant adenovirus vectors Ad.RSVfJgal (cod-
ing for Escherichia coli fJ-galactosidase) and AdalAT (coding 
for human al-antitrypsin) were used in both ex vivo 
and in vivo approaches. Following in vitro infection with 
Ad.RSVfJgal, murine keratinocytes expressed fJ-galactosi-
dase. Parallel in vitro studies with AdalAT documented de 
novo synthesis and secretion of human alA T as shown by 
[35S]methionine labeling and immunoprecipitation. Quanti-
fication of human alAT in the culture supernatants demon-
strated 0.1-0.3 J1.g human a1AT secreted/ml-24 h. Evalua-
G ene therapy represents a therapeutic strategy to use genetic information as the pharmacologic agent. Originally conceived as a strategy to treat hereditary disease, it is now recognized that gene therapy repre-sents a powerful approach to deliver therapeutic pro-
teins for local and/or systemic use [1-4]. There are two basic ap-
proaches to gene therapy, ex 1Ii110 and in lIillo. In the ex lIillo approach, 
cells are removed from the potential recipient, the cells are modified 
in the laboratory, and the genetically modified cells are returned 
to the recipient. Examples of the ex lIillo strategy used in human 
studies include modification of T lymphocytes for the treatment 
of adenosine deaminase deficiency, hepatocytes for familial hy-
percholesterolemia, and tumor-infiltrating lymphocytes for neo-
plastic disease [S - 7]. In the ill lIillo method, the gene is transferred 
directly to the recipient. This approach has been used in human 
studies for the treatment of cystic fibrosis and neoplastic disease 
[8,9]. 
The skin has the potential for a variety of gene therapy applica-
tions. It is the largest organ of the body and is highly vascular, and 
thus is an ideal site for systemic delivery of gene products. Because 
of its accessibility, both ex lIillo and ill lIillo strategies are applicable to 
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tion of the serum of mice receiving transplants (105 cells/ 
mouse) of Ada1AT-infected syngeneic keratinocytes dem-
onstrated human a1AT for at least 14 d with maximum 
levels of 41 ng/m!. To demonstrate the feasibility of direct 
adenovirus-mediated in vivo transfer of genes to the skin, 
Ad.RSVfJgal or Ada1AT were administered subcutaneously 
to mice. Histologic evaluation after 4 d demonstrated ex-
pression of fJ-galactosidase in various types of skin cells. 
Quantification of human alA T in serum of animals infected 
subcutaneously with AdalAT showed levels of 53 ng/ml at 
day 4, with human a1AT detectable for at least 14 d. These 
observations support the feasibility of ex Ilivo and in VillO gene 
transfer to the skin mediated by replication-deficient adeno-
virus vectors. Key words: gene therapy/a1-antitrypsin/fJ-galacto-
sidase/keratinocyte. ] bzvest Dermatol 102:415 - 421, 1994 
the skin, using the epidermis, dermis, or subcutaneous tissues as the 
site for transfer of modified cells or direct transfer of genes. Gene 
therapy strategies that have been evaluated in the skin include trans-
plantation of fibroblasts and keratinocytes modified by plasmids or 
retrovirus vectors [10-20]. 
The present study is directed toward evaluation of a new strategy 
for gene therapy to the skin, the use of replication-deficient recom-
binant adenovirus (Ad) vectors for both ex vivo and in lI illo ap-
proaches. Ad vectors have a number of advantages as gene transfer 
vehicles, including: 1) they can be rendered replication deficient; 2) 
Ad can be manipulated to include at least 7.5 kb of exogenous 
DNA; 3) Ad vectors have been successful in transferring genes to a 
variery of cell types illllitro and in 1Ii110 [2,4,8,21 - 33], and 4) there is 
evidence of minimal risk from these vectors in that there is no 
known association of malignancy with adenovirus infection in 
humans [34,35] . Further, type 5 Ad (the type used for the construc-
tion of the vectors used in this study) are categorized in subgroup C, 
a subgroup that is non-tumorigenic in experimental animals [36] . 
And, finally, there is extensive clinical experience regarding the 
administration of live adenovirus vaccines in humans with no re-
ports of association with malignancy [37]. 
To evaluate this strategy, we have used two Ad vectors, 
Ad.RSVpgal (an E1- E3- AdS-based vector containing the Esche-
richia coli p-galactosidase [,Bgal] gene), as an example of transfer of a 
gene coding for an intracellular protein, and Ada1AT (an E1- E3-
AdS-based vector containing the human a1-antitrypsin [a1AT] 
cDNA), as an example of a gene coding for a typical secreted pro-
tein. Both vectors were evaluated in an ex lIillo strategy using kerati-
nocytes as the cell to be modified, and an in lIillo strategy where the 
Ad vectors were injected directly into the skin. 
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Figure 1. .Adenovirus-mediated.gene transfer of th~ E. coli lacZ (fJ-galactosid~se) gene. to keratin?cytes ill vitro. a) Keratinocytes, untrea.ted; b) ~eratinocytes 
infected with AdCFTR; c) keratmocytes mfected with Ad.RSVpgal; d) keratmocytes infected with Ad.RSVpgal. All samples were stamed with the X-gal 
reagent for p-galactosidase. Bar, 50 j.tm. 
MATERIALS AND METHODS 
Adenovirus Vectors The structures, propagation, purification, and titer-
ing of the three replication-deficient recombinant Ad vectors used in this 
study, Ad.RSV-pgal, AdalAT, and AdCFTR, have been previously de-
scribed [22,23,25,27,38,391. Briefly, all are EI-, E3- vectors based on Ad 
rype 5 but where Ad.RSV -pgal contains the n~c1ear localizing signal of the 
SV 40 T antigen and uses the Rous sarcoma ViruS long tenntnal repeat as a 
promoter to drive the E. coli lacZ (p-galactosidase) gene, both AdalAT and 
AdCFTR use the Ad rype 2 major late promoter (MLP) and tripartite leaders 
to drive the human al-antitrypsin (alAT) eDNA, or human cystic fibrosis 
transmembrane conductance regulator (CFTR) eDNA, respectively. All 
preparations of AdalAT were evaluated by enzyme-linked immunosorbent 
assay (ELISA) to insure there was no contaminating human alAT [401. 
Cell Culture and I II Vitro Infection Epidermal cells were obtained from 
newborn mice (C57b/6N) as described by Yuspa and Harvis [41], and cul-
tured in serum-free MCDB 153 media [421 (Clone tics Co., San Diego, CA) 
containing 50 j.tM Ca+++. Newborn mice (1- 3 d post-partum) were euth-
anized and washed with Betadine solution (Purdue Frederick Co., Yonkers, 
NY) followed by 70% ethanol. The skin was removed with forceps. 
Stretched skin was floated on 0.25% trypsin at 4 ° C for 18 h, after which the 
epidermis and dermis could be separated as independent sheets. The epider-
mis was minced and stirred in culture medium containing serum to inhibit 
the action of residual trypsin and to release epidermal cells. The resultant cell 
suspension was filtered through nylon mesh (Nytex 157; Martin Supply 
Inc., Baltimore, MD) to remove the stratum corneum. The cells were 
counted, aliquoted at 1.5 X 105 cells/6-cm plate, and grown at 37°C until 
80% confluent. They were then infected with Ad.RSVpgal, AdalAT, or 
AdCFTR at a multipliciry of infection (MOl) of 10 plaque forming units 
(pfu)/cell in 1 ml of serum-free MCDB 153 media for 90 min. The incuba-
tion was continued with the addition of the serum-free MCDB 153 media 
described above. 
III Vitro Gene Expression in Murine Keratinocytes Keratinocytes 
were infected with Ad.RSVpgal (or controls) and after 24 h the E. coli lacZ 
gene product (p-galactosidase) was detected by fixing, washing, and staining 
the keratinocytes with X-gal reagent (5-bromo-4-chloro-3-indolyl-P-D-
galactopyranoside; Boehringer Mannheim, Indianapolis, IN) as previously 
described [24,43]. Expression of the E. coli lacZ gene was considered positive 
when a nuclear dominant blue color was observed. 
After infection of keratinocytes with AdalAT (or controls) the de tJovo 
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Figure 2. Synthesis and secretion of human aI-antitrypsin (alAT) by 
murine keratinocytes followi ng ill vitro infection with the recombinant ade-
novirus Ad-alAT containing the human alATcONA. A) De tlOVO biosyn-
thesis of human alAT by the keratinocytes. Shown are SOS-polyacrylamide 
gel analyses of supernatants o~kerat!nocytes incubated 24 h with [35SJ~et.hi­
onine followmg 24-h mfectlOn with AdalAT, and ImmunopreclpltatlOn 
with an anti-human alAT antibody prior to analysis. Lalle 1) uninfected 
cells; latle 2) cells infected with the control vector AdCFTR; latle 3) cells 
infected with AdalAT; lane 4: same as latle 3 but immunoprecipitation 
carried out with excess unlabeled alAT. B) Quantitation of the amount of 
human alAT secreted by murine keratinocytes infected with AdalAT itl 
vitro. Human alAT levels in the supernatants were quantified by ELISA 
24 h after infection. The detectable threshold of the ELISA is 3 ng/ml. Each 
data point represents the average of fWo determinations of individual sam-
ples. . 
synthesis and secretion of h~man alAT wa~ e~aluated by culturin~ ~he 
keratinocytes m 6-cm plates m 2 ml of metlllorune-free media contallllllg 
[3sSJ-methionine (500,£lCi, 1233 Ci/mmol; New England Nuclear, Bos-
ton, MA). After 24 h, supernatants were collected and evaluated by immu-
noprecipita~ion with an anti-human alAT ~ntibody (Boehringer !'1ann-
heim), sodIUm dodecyl sulfate polyacrylamide gel electrophoresIs, and 
autoradiography [22,44]. The amount of human alAT secreted by the 
keratinocytes infected with AdalAT was deter'mined after 24 h using an 
enzyme-linked immunosorbent assay (ELISA) capable of detecting> 3 ng/ 
rol of human alAT. 
Transplantation of Keratinocytes Infected with AdalAT Mouse 
(C57b/6N) keratinocytes were isolated and infected with AdalAT (control 
AdCFTR or phosphate-buffered saline [PBS)) as described above, cultured 
for 2 d, trypsinized, and washed with PBS to eliminate any contamination 
from secreted human aIAT. The cells were then implanted (105 cells/ani-
mal) into the subcutaneous tissues of the flank of CS7b/6N mice. Serum 
samples for the analysis of alA T levels were obtained by terminal cardiac 
puncture from individu~l mice ov~r the next 7 - 21 d. Controls included 
uninfected cells or cells mfected With AdCFTR. 
In Vivo Adenovirus-Mediated Gene Transfer To eva luate the transfer 
of the E. coli lacZ gene or human alAT cONA to CS7b/6N mice skin itl 
vivo, mice were anesthetized with methoxyflurane (Metofane, Pitman-
Moore, Mundelein, IL). The dorsal surface was shaved, sterilized with io-
dine and alcohol, and 5 X 108 pfu Ad.RSVpgal or AdalAT were injected 
subcutaneously. To evaluate p-galactosidase activity in the skin of mice 
infected it! vivo with Ad.RSVpgaJ (or controls), 4 d after infection the mice 
were anesthetized with methoxyflurane and killed. The skin was removed 
and stained with X-Gal as described above. 
To evaluate the ability of subcutaneous administration of AdalAT to 
deliver human alAT to the systemic circulation, AdalAT was injected as 
described above and serum al AT levels were evaluated by ELISA (see above) 
at 1 h (referred to as 0 time) or 2-14 dafter AdalAT administration. As 
controls, animals received the same amount of' the control vector 
Ad.RSVpgal or PBS. 
RESULTS 
Adenovirus-Mediated Gene Transfer to Keratinocytes To 
evaluate the feasibility of adenovirus-mediated gene transfer to ker-
atinocytes, primary murine keratinocytes were infected in vitro with 
Ad.RSVpgal or controls (AdCFTR or PBS) (Fig 1). In the keratino-
cytes treated with PBS or AdCFTR, X-Gal staining revealed no 
blue color, i.e., no p-galactosidase activity (Fig la,b). In contrast, 
24 h after infection with Ad.RSVpgal, X-Gal staining showed ex-
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tensive blue color localized predominantly to the nuclei, indicative 
of p-galactosidase activity from the transfer into and expression in 
the cells of the E. coli lacZ gene by Ad.RSVpgal (Fig Ic,d). 
Evaluation of primary murine keratinocytes for the synthesis and 
secretion of alAT demonstrated that uninfected keratinocytes or 
keratinocytes infected with AdCFTR did not synthesize and se-
creted human alAT (Fig 2A, larles 1,2). In contrast, de 110VO biosyn-
thesis and secretion of human alAT was clearly demonstrated 24 h 
after AdalAT infection (Fig 2A, lal1e 3). This protein was specifi-
cally human a1AT, as shown by blocking of the anti-human alAT 
antibody using excess amount of unlabeled human alAT (Fig 2A, 
lane 4). Quantitation of human a1AT 24 h after infection of the 
primary keratinocytes with Ad-aIAT demonstrated a.n average 
level of 246 ± 48 ng/ml of culture supernatant (Fig 2B). In the 
context that the confluent plates contained approximately 5 X 105 
cells under 5 ml of media, the keratinocytes were producing about 
2-3 J1.g human alAT/106 cells/24 h . 
Transplantation ofKeratinocytes Infected In Vitro with Ad-
a1AT To evaluate the capacity of il'l vitro Ad-infected keratino-
cytes to supply an exogenous gene product to the circulation 
after tra.nsplantation, primary keratinocytes were infected with 
AdalAT, or, as controls, AdCFTR or exposed to PBS. After 2 d 
incubation in vitro, the cells were injected subcutaneously into syn-
geneic mice. No human alAT could be detected in any serum 
samples of mice tra.nsplanted with the keratinocytes infected with 
the control vector AdCFTR or with keratinocytes exposed to PBS 
alone (Fig 3). In contrast, human alAT was present in the serum of 
mice transplanted with AdalAT -treated keratinocytes for at least 
14 d, with a maximum 41 ± 6 ng/ml (mean ± SE) at day 14. 
Adenovirus-Mediated In Vivo Gene Transfer To evaluate in 
l1ivo Ad-mediated gene transfer to the skin, Ad. RSVpgal or 
AdCFTR or PBS as controls, were injected subcutaneously (Fig 4). 
Skin from mice receiving subcutaneous injections of AdCFTR (Fig 
4a) or PBS (not shown) revealed no blue color following X-Gal 
staining, i.e., no p-galactosidase activity at the macroscopic level nor 
microscopic level (AdCFTR, Fig 4c; PBS, not shown). In contrast, 
4 d after injection with Ad.RSVpgal, p-galactosidase activity was 
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Figure 3. Quantitation of the amount of human alAT in sera from mice 
following subcutaneous transplantation of murine keratinocytes infected 
with AdalAT ex vivo. Each symbol represents a unique mouse. In individual 
mice human alAT levels in serum were quantified by ELISA 1 d before 
transplantation (time = 0) and 7,14, or 21 d after transplantation ofkerati-
nocytes infected with Ada1AT (e) 2 d prior to transplantation, or as con-
trols infected with AdCFTR (0) 2 d prior to transplantation or exposed to 
PBS (6) 2 d prior to transplantation. 
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Figure 4. In vivo transfer of the E. coli lacZ gene to mouse skin. Four days after Ad.RSVpgal was injected subcutaneously, the skin was evaluated for the 
presence of the lacZ product (blue stainit'g, pgal) usi~g X-gal stain. ~) Skin from a mouse infected with control vector AdCFTR showing no fJgal expression; b) 
skin from a mouse infected with Ad.RSV pgal showmg pgal expressIon (blue color); c) skin section from a mouse infected with control vector AdCFTR showing 
nO pgal activity; d) skin section from a mouse infected with Ad.RSVpgal showing pgal expression in keratinocytes , sebaceous cells, smooth muscle cells, and 
fibroblasts. 
observed at the macroscopic level (Fig 4b) and in various edl types in 
the epidermis and dermis including keratinocytes (Fig 4d,e) , se-
baceous cells (Fig 4d,f), smooth muscle cells (Fig 4d,j,g) , fibroblasts 
(Fig 4d,e,h), and adirocytes (Fig 4h). 
The chronicity 0 gene expression following ill vivo a.dministra-
tion of an adenovirus vector was demonstrated by quantifying 
human alAT levels in sera from mice evaluated up to 14 dafter 
subcutaneous administration of AdalAT. No human alAT could 
be detected in any serum samples of mice receiving, a.s controls, 
subc~taneous AdCFTR or PBS (Fig 5). In contrast, human alAT 
could be detected in the serum of mice 2 d after subcutaneous ad-
ministration of AdalAT at 5 X 108 pfu/mouse. Human alAT 
levels peaked at day 4 with a mean of 53 ± 5 ng/ml. The levels 
declined thereafter, but remained detectable for at least 14 d. 
DISCUSSION 
Gene therapy represents a therapeutic strategy where genetic infor-
mation is used as the pharmacologic agent. To date, most ap-
proaches to gene therapy for skin have focused on ex vivo strategies 
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Figure 4 (Continued). e) Same as (d) but higher magnification, showing figal expression in keratinocytes and fibroblasts;!) same as (e) but showing figal 
expression in sebaceous cells; (g) same as (e) but showing figal expression in smooth muscle cells; h) same as (e) but showing figal expression in fibroblasts and 
adipocytes. All sections were counterstained with nuclear fast red. Bar, 50 11m. 
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Figure 5. Human alA T levels in sera of mice following subcutaneous 
administration of AdalAT. In individual mice human alAT levels were 
quantified by ELISA 1 d before infection (time = 0),2,4,7, or 14 dafter 
infection. Shown are data and means for animals infected with AdalAT (e), 
the control vector AdCFTR (&), and PBS (0). Each point, mean of duplicate 
determination for a unique mouse. The detectable threshold of the ELISA is 
3 ng/mi. 
utilizing vectors such as retroviruses to insert genes into autologous 
cells in vitro, followed by transplantation of the genetically modified 
cells to the recipient. The present study is directed toward evalua-
tion of a new strategy for gene therapy to the skin, the use of 
replication-deficient recombinant adenovirus vectors both ex vivo 
and in vivo. The data demonstrate that this strategy is feasible, with 
adenovirus vectors capable of transferring genes to keratinocytes ill 
vitro and the modified cells transplanted to the recipient, as well as itl 
vivo, where the adenovirus vectors transfer genes directly to skin 
cells in vivo. 
Keratinocytes have a number of features favorable for various 
gene transfer applications. They are easily obtained by biopsy and 
can be maintained in culture in defined media [42,45]. Keratino-
cytes are capable of secreting a variety of proteins that have local or 
distant sites of action [46,47]. Examples of proteins that could be 
supplied by ex vivo strategies using keratinocytes for gene transfer 
include growth hormone and factor IX [1,2,4,11,15]. The data in 
the present study demonstrate that adenovirus-mediated gene 
transfer to keratinocytes in vitro with subsequent transplantation is 
an efficient strategy to deliver a gene product for local or distant area 
for several days. It is not clear, however, why the expression of the 
exogenous gene decreases after 2 weeks. It may be associated with 
the survival of the transplanted cells; keratinocytes have a limited 
life-span [48]. Alternatively, all available evidence suggests that the 
adenovirus genome functions in an extrachromosomal fashion [34] 
and it is possible that endogenous nucleases destroy the transferred 
DNA. 
Advantages of in vivo gene transfer strategies for gene therapy to 
the skin are the ease of accessibility of the tissue and the less invasive 
nature of this approach compared to ex vivo gene transfer and trans-
plantation. Direct subcutaneous injection of adenovirus vectors re-
sults in gene transfer to epidermal keratinocytes, fibroblasts, and 
smooth muscle cells as well as cells comprising hair follicles and 
sebaceous glands, cells for which ex vivo gene transfer would be 
difficult. However, the adenovirus-mediated itl vivo gene transfer to 
the skin was not homogeneously distributed. This may be-related to 
the degree of exposure of various cells to the vector and/or variable 
susceptibility of different target cells to adenovirus infection. Al-
though a single subcutaneous injection of Ada1AT resulted in 
levels of human alAT in the mouse that would be below that level 
normally required for supplementation in a1-antitrypsin deficiency 
in humans, the adenovirus-mediated in vivo strategy has the poten-
tial to be optimized by alterations in site(s) and number of, adminis-
trations, dosage(s) and/or vector design. Finally, with the caveat 
that multiple factors influence serum protein concentrations, mak-
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ing it difficult to compare unrelated serum protein levels, it may be 
possible to provide sufficient gene product for therapeutic applica-
tions such as supplementation of factors VIn and IX, growth hor-
mone, or erythropoietin where the levels achieved with the adeno-
virus-based ill vivo strategy lie within the range currently achieved 
with direct supplementation therapies with these proteins [49 - 51]. 
We thatlk Dr. Ulrike Lichti, Laboratory oj Celllilar CarcitlogetJesis and Tumor 
Promotion, NCr, Jor helpJul suggestions regarding culturing keratinocytes. 
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ANNOUNCEMENT 
The 43rd Annual Symposium on the Biology of Skin will be held in Snowmass, Colorado 
August 6-10, 1994. The topic of this year's meeting will be "Lymphocytes in Skin Disease: 
From Activation to Immunodeficiency." 
The meeting will consist of invited oral and poster presentations. Enrollment is limited to 
150 participants. A limited number of posters will be accepted for presentation. Deadline for 
poster abstract submission is June 1, 1994. Those wishing to submit abstracts for poster presen-
tations or requesting registration materials should write to David A. Norris, M.D., The Cuta-
neous Biology Foundation, Box B-144, Department of Dermatology, University of Colorado 
School of Medicine, 4200 E. Ninth Avenue, Denver, CO 80262. 
